Floatz logo

Tigozertinib

Antineoplastic Agents

Blueprint Medicines CorporationSmall moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

66 Active assets in the Antineoplastic Agents cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4A
Palonosetron
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4A
Phosphonic acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-2,5-dihydro-5-oxo-1H-1,2,4-triazol-1-yl]-
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BBB
Netupitant
Instituto Brasileiro de Controle do Cancer
Phase 3BB
Docetaxel
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 4BB

View all 50 →

Same molecule, other indications

Tigozertinib is also rated in:

respiratory system disorderDormant
CC
Indicative ·
43 / 100
View asset →
respiratory tract neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
bronchogenic carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →